CD274 and neoplasm: Biomarkers of response exist at the tumor level (PD-L1 expression by tumor cells or tumor-infiltrating cells, a high tumor mutational burden, and microsatellite instability-high (MSI-H) or Mismatch Repair-deficiency (dMMR) status), but there is a lack of circulating biomarkers easily usable in the clinical practice (6).